secwatch.observer — SEC 8-K summary
======================================

Issuer:     FATE THERAPEUTICS INC (FATE)
CIK:        0001434316
Form:       8-K
Filed at:   2025-05-13T23:59:59+00:00
Accession:  0000950170-25-070280
Event type: other_material
Sentiment:  positive
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Fate Therapeutics Q1 cash $272.7M; FT819 gets RMAT designation for SLE
----------------------------------------------------------------------

- Cash, equivalents, and investments $272.7M as of March 31, 2025; projected runway through 1H27.
- FT819 granted RMAT designation by FDA for moderate-to-severe SLE; new data at EULAR June 11.
- Phase 1 study expanded to include AAV, IIM, SSc autoimmune disease cohorts; enrollment ongoing.
- Revenue $1.6M from Ono collaboration; total operating expenses $42.9M (R&D $29.1M, G&A $13.8M).
- Common shares outstanding 114.6M; preferred shares (convertible 5:1) 2.8M; pre-funded warrants 3.9M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/0000950170-25-070280-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1434316/000095017025070280/fate-20250513.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-070280

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer